20/20 GeneSystems, Inc.

Overview
Resources
Videos

20/20 BioLabs develops and commercializes cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. Our advanced diagnostics leverage machine learning algorithms built on extensive real-world data, offering exceptional accuracy and convenience for individuals and providers.

We pioneer affordable, accurate, actionable tests that can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles.

(We call these advantages our “straight A’s

Key Benefits:

AI-driven results:
Enhanced accuracy through machine learning algorithms trained on data from tens of thousands of individuals tested months or years before being diagnosed with cancer.
CAP Accredited & CLIA Licensed laboratory
ensuring the highest standards of accuracy and reliability.
Our MCED performed well in blinded studies conducted by the U.S. National Cancer Institute and our biomarker approach is supported by studies conducted by the MD Anderson Cancer Center and other leading academic medical centers.